Adam Schiffenbauer1, Sara Faghihi-Kashani2, Terrence P O'Hanlon2, Willy A Flegel3, Sharon D Adams3, Ira N Targoff4, Chester V Oddis5, Steven R Ytterberg6, Rohit Aggarwal5, Lisa Christopher-Stine7, Ejaz A Shamim8, Paul F Dellaripa9, Sonye K Danoff10, Andrew L Mammen11, Frederick W Miller2. 1. Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD. Electronic address: schiffenbauera2@niehs.nih.gov. 2. Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD. 3. Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD. 4. Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK. 5. Myositis Center, University of Pittsburgh School of Medicine, Pittsburgh, PA. 6. Division of Rheumatology, Mayo Clinic, Rochester, MN. 7. Johns Hopkins Myositis Center, Johns Hopkins University School of Medicine, Baltimore, MD; Departments of Neurology and Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 8. Department of Neurology, Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD. 9. Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA. 10. Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD. 11. Departments of Neurology and Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.
Abstract
OBJECTIVE: Cigarette smoking is associated with immune-mediated disorders. We explored the contribution of smoking to polymyositis (PM) and dermatomyositis (DM) phenotypes and attempted to determine whether cigarette smoking effects differ by race and genotype. METHODS: Associations of tobacco smoking with disease features, autoantibodies, HLA types, and race were evaluated using multiple logistic regressions in 465 patients. RESULTS: Caucasian ever-smokers (n = 140) were more likely to have PM (adjusted OR = 2.24, 95% CI: 1.41\x963.57), anti-synthetase (adjusted OR = 1.93, 95% CI: 1.12\x963.34) and anti-Jo-1 autoantibodies (adjusted OR = 1.94, 95% CI: 1.08\x963.46) and less likely to have anti-p155/140 autoantibodies (adjusted OR = 0.36, 95% CI: 0.14\x960.92). In Caucasians, ever-smokers had a greater interstitial lung disease (ILD) frequency than never-smokers, while in African-Americans this relationship was inverted, but neither trend reached statistical significance. Pack-years of cigarette smoking showed significant positive associations with PM (adjusted OR = 1.02, 95% CI: 1.002\x961.04) and ILD (adjusted OR = 1.02, 95% CI: 1.001\x961.03) and was inversely associated with anti-p155/140 autoantibodies (adjusted OR = 0.93, 95% CI: 0.87\x960.99) in Caucasians. Caucasian heavy smokers (=20 pack-years) were more likely to have PM (adjusted OR = 2.52, 95% CI: 1.25\x965.09), ILD (adjusted OR = 2.48, 95% CI: 1.23\x965.00) and anti-Jo-1 autoantibodies (adjusted OR = 2.65, 95% CI: 1.16\x966.08) than never-smokers. In Caucasians, compared to never-smokers without HLA-DRB1*03:01 allele, ever-smokers with HLA-DRB1*03:01 allele had the highest odds of PM, ILD, ASA, and anti-Jo-1 autoantibodies. Risks for those with only one of these two factors were intermediate. An inverse pattern was observed regarding anti-p155/140 autoantibodies. CONCLUSION: Tobacco smoking was associated with clinical and autoantibody phenotypes in Caucasians. Our findings also suggest possible interactions among HLA-DRB1*03:01 and smoking on the risk of PM and ILD, as well as, anti-synthetase, anti-Jo-1, and anti-p155/140 autoantibodies in Caucasians.
OBJECTIVE: Cigarette smoking is associated with immune-mediated disorders. We explored the contribution of smoking to polymyositis (PM) and dermatomyositis (DM) phenotypes and attempted to determine whether cigarette smoking effects differ by race and genotype. METHODS: Associations of tobacco smoking with disease features, autoantibodies, HLA types, and race were evaluated using multiple logistic regressions in 465 patients. RESULTS: Caucasian ever-smokers (n = 140) were more likely to have PM (adjusted OR = 2.24, 95% CI: 1.41\x963.57), anti-synthetase (adjusted OR = 1.93, 95% CI: 1.12\x963.34) and anti-Jo-1 autoantibodies (adjusted OR = 1.94, 95% CI: 1.08\x963.46) and less likely to have anti-p155/140 autoantibodies (adjusted OR = 0.36, 95% CI: 0.14\x960.92). In Caucasians, ever-smokers had a greater interstitial lung disease (ILD) frequency than never-smokers, while in African-Americans this relationship was inverted, but neither trend reached statistical significance. Pack-years of cigarette smoking showed significant positive associations with PM (adjusted OR = 1.02, 95% CI: 1.002\x961.04) and ILD (adjusted OR = 1.02, 95% CI: 1.001\x961.03) and was inversely associated with anti-p155/140 autoantibodies (adjusted OR = 0.93, 95% CI: 0.87\x960.99) in Caucasians. Caucasian heavy smokers (=20 pack-years) were more likely to have PM (adjusted OR = 2.52, 95% CI: 1.25\x965.09), ILD (adjusted OR = 2.48, 95% CI: 1.23\x965.00) and anti-Jo-1 autoantibodies (adjusted OR = 2.65, 95% CI: 1.16\x966.08) than never-smokers. In Caucasians, compared to never-smokers without HLA-DRB1*03:01 allele, ever-smokers with HLA-DRB1*03:01 allele had the highest odds of PM, ILD, ASA, and anti-Jo-1 autoantibodies. Risks for those with only one of these two factors were intermediate. An inverse pattern was observed regarding anti-p155/140 autoantibodies. CONCLUSION:Tobacco smoking was associated with clinical and autoantibody phenotypes in Caucasians. Our findings also suggest possible interactions among HLA-DRB1*03:01 and smoking on the risk of PM and ILD, as well as, anti-synthetase, anti-Jo-1, and anti-p155/140 autoantibodies in Caucasians.
Authors: Dennis R Trinidad; Eliseo J Pérez-Stable; Martha M White; Sherry L Emery; Karen Messer Journal: Am J Public Health Date: 2011-02-17 Impact factor: 9.308
Authors: R B Gonçalves; R D Coletta; K G Silvério; L Benevides; M Z Casati; J S da Silva; F H Nociti Journal: Inflamm Res Date: 2011-02-05 Impact factor: 4.575
Authors: Simon Rothwell; Robert G Cooper; Ingrid E Lundberg; Frederick W Miller; Peter K Gregersen; John Bowes; Jiri Vencovsky; Katalin Danko; Vidya Limaye; Albert Selva-O'Callaghan; Michael G Hanna; Pedro M Machado; Lauren M Pachman; Ann M Reed; Lisa G Rider; Joanna Cobb; Hazel Platt; Øyvind Molberg; Olivier Benveniste; Pernille Mathiesen; Timothy Radstake; Andrea Doria; Jan De Bleecker; Boel De Paepe; Britta Maurer; William E Ollier; Leonid Padyukov; Terrance P O'Hanlon; Annette Lee; Christopher I Amos; Christian Gieger; Thomas Meitinger; Juliane Winkelmann; Lucy R Wedderburn; Hector Chinoy; Janine A Lamb Journal: Ann Rheum Dis Date: 2015-09-11 Impact factor: 19.103
Authors: Md M Hossain; Jesse Wilkerson; John A McGrath; Payam N Farhadi; Cole Brokamp; Md T F Khan; Bob Goldberg; Hermine I Brunner; Maurizio Macaluso; Frederick W Miller; Lisa G Rider Journal: Front Med (Lausanne) Date: 2022-03-16